Jardiance vs Tresiba: What to Do When One Fails

What "Failure" Actually Means With These Two Drugs

Most of the time, your HbA1c rising on Jardiance does not mean Jardiance failed. It means Jardiance has done everything it can do through its single mechanism, and basal insulin coverage is now also needed. Tresiba and Jardiance fix different problems.

Jardiance works by blocking the SGLT2 transporter in your kidney, forcing roughly 70 grams of glucose out through urine each day. That glucose loss lowers HbA1c by approximately 0.5 to 1.0 percentage points on average. It does not touch the liver's overnight glucose output or postprandial spikes in any meaningful direct way.

Tresiba is a long-acting basal insulin. It provides a flat, nearly peakless 24-hour insulin background that suppresses hepatic glucose production overnight. Its coefficient of variation for day-to-day pharmacodynamic variability is approximately 20%, roughly half that of insulin glargine U-100. This stability matters a great deal if you are prone to nocturnal hypoglycemia.

The Three Clinical Scenarios Called "Failure"

Before your clinician changes anything, she should identify which scenario you are actually in:

1. Jardiance plateau. Your HbA1c dropped initially on empagliflozin but has been creeping up for six or more months despite adherence. This usually means progressive beta-cell decline, and adding basal insulin is the logical next step.
2. Tresiba dose ceiling. Your fasting glucose is at target on Tresiba but post-meal readings and overall HbA1c remain elevated. Adding an SGLT2 inhibitor here is a guideline-supported option, not a rescue move.
3. True drug intolerance. Jardiance is causing recurrent genitourinary infections you cannot tolerate, or Tresiba is causing symptomatic hypoglycemia despite multiple dose reductions. Only in this scenario does replacement rather than combination make sense.

Why Women Hit Each Ceiling Differently

Women with type 2 diabetes carry a 44% higher relative risk of fatal coronary heart disease compared with men with the same diagnosis, which is one reason the cardiovascular protection from Jardiance carries particular weight in female patients. At the same time, women are more likely to develop recurrent vulvovaginal candidiasis on SGLT2 inhibitors because the glucosuria creates a sugar-rich vaginal environment. That side effect is the most common reason women discontinue Jardiance prematurely, even when it is working metabolically.

Tresiba dose requirements in women fluctuate across the menstrual cycle. Progesterone-dominant phases (days 14 to 28 of a typical cycle) drive insulin resistance upward by 10 to 25%, meaning your Tresiba dose that felt perfect in the follicular phase may be insufficient by the luteal phase.

Life Stage by Life Stage: Which Drug Fits Better

Reproductive Years (Ages 18 to 40)

In women with type 2 diabetes who are still having regular periods, Jardiance is generally preferred as an early add-on because it carries no hypoglycemia risk when used without insulin, it supports modest weight loss of 2 to 3 kg on average over 24 weeks, and it does not require injection. Tresiba enters the picture when fasting hyperglycemia persists despite SGLT2 inhibition and oral agents.

Contraception is not optional if you are on Tresiba and planning a pregnancy. Basal insulin itself is safe and actually preferred in pregnancy, but the transition requires careful planning because your insulin requirements increase substantially across each trimester.

Trying to Conceive

ACOG recommends pre-conception HbA1c below 6.5% to minimize fetal risk. If your HbA1c is above that threshold and you are trying to conceive, Jardiance must be discontinued before conception attempts or as soon as pregnancy is confirmed. Tresiba or another basal insulin is then the preferred glucose-control backbone throughout pregnancy.

Perimenopause (Typically Ages 45 to 55)

Perimenopause changes the calculus significantly. Fluctuating estrogen levels worsen insulin resistance episodically, making glycemic control less predictable. The Menopause Society (formerly NAMS) recognizes that menopause transition is associated with worsening glycemia and increased visceral adiposity independent of aging.

Jardiance may be particularly useful here because its mechanism is insulin-independent, weight-neutral to modestly weight-reducing, and does not require dose titration during hormonal swings. However, if your estimated glomerular filtration rate (eGFR) has begun to decline as it commonly does in the fifth decade, Jardiance's glucose-lowering power diminishes: at eGFR below 45 mL/min/1.73m², empagliflozin is no longer effective for glucose control, though it can still be continued for its heart and kidney protective effects down to an eGFR of 20 mL/min/1.73m² per current FDA labeling.

Tresiba may need dose increases during perimenopause to match rising insulin resistance, particularly if you notice fasting glucose creeping up despite what previously was an adequate dose.

Post-Menopause

Post-menopausal women lose the partial cardiovascular protection that estrogen provided. The EMPA-REG OUTCOME trial enrolled a mixed-sex population, and subgroup analyses showed women derived the cardiovascular mortality benefit, though the trial was not powered for sex-stratified conclusions. Jardiance's kidney-protective effects become increasingly important post-menopause, when diabetic nephropathy risk accumulates.

The DEVOTE trial showed that insulin degludec produced [40% fewer severe hypoglycemic events than insulin glargine U-100 at equivalent HbA1c reduction], with nocturnal hypoglycemia reduced by 53%. For older post-menopausal women, this matters because hypoglycemia-associated falls carry serious fracture risk, and post-menopausal bone density is already declining.

The EMPA-REG OUTCOME and DEVOTE Trials: What They Actually Showed Women

EMPA-REG OUTCOME (NEJM, 2015)

This trial randomized 7,020 adults with type 2 diabetes and established cardiovascular disease to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

Empagliflozin reduced the composite endpoint by 14% relative to placebo. Cardiovascular death specifically fell by 38%. Hospitalization for heart failure dropped by 35%. These are not small effects.

The trial did not include a direct comparison with Tresiba. Women made up approximately 28% of the EMPA-REG population, a representation gap that limits sex-specific conclusions. The HbA1c reduction in the trial was modest (approximately 0.5 percentage points), which underscores that Jardiance's cardiovascular benefit appears to be largely independent of its glucose-lowering effect.

DEVOTE (NEJM, 2017)

DEVOTE was a cardiovascular outcomes trial comparing insulin degludec with insulin glargine U-100 in 7,637 adults with type 2 diabetes at high cardiovascular risk. Degludec was non-inferior to glargine for major adverse cardiovascular events.

The clinically important finding for women was the hypoglycemia data. Severe hypoglycemia occurred in 4.9% of the degludec group versus 6.6% of the glargine group (rate ratio 0.60). Nocturnal severe hypoglycemia was reduced by 53% with degludec. Women were approximately 34% of DEVOTE participants, again a gap that limits direct extrapolation.

Neither trial asked the question "what happens when the other drug fails," so any guidance on sequencing is based on mechanism, expert consensus, and real-world data rather than head-to-head switching trials.

What to Do Step by Step When Jardiance Is No Longer Enough

This framework is designed specifically for women with type 2 diabetes whose HbA1c has risen above target on maximally tolerated empagliflozin plus at least one other oral agent.

Step 1: Confirm true pharmacological failure, not adherence or lifestyle drift. Recheck HbA1c after confirming consistent medication use, stable diet, and no recent acute illness. Stress, illness, and steroid use can spike HbA1c transiently.

Step 2: Check your eGFR and urine albumin-to-creatinine ratio. If eGFR is below 45, Jardiance is no longer contributing meaningfully to glucose control. Continue it for kidney and cardiac protection if eGFR is still above 20, but add Tresiba for the glucose work.

Step 3: Start Tresiba at 10 units once daily at the same time each day. The FDA-approved starting dose for insulin-naive patients is 10 units subcutaneously once daily, with titration upward by 2 units every three days until fasting glucose consistently reaches 80 to 130 mg/dL. Do not stop Jardiance when you add Tresiba unless there is a specific contraindication.

Step 4: Anticipate a Tresiba dose reduction if you also continue Jardiance. The combined glucose-lowering effect means your final Tresiba dose will typically be 10 to 20% lower than if Tresiba were used alone. Your clinician should monitor for hypoglycemia in the first four to eight weeks.

Step 5: Revisit Jardiance dose and continuation at three months. If eGFR is adequate, continuing both drugs gives you overlapping glycemic coverage, cardiovascular protection from empagliflozin, and basal coverage from degludec.

What to Do When Tresiba Is No Longer Enough

Tresiba can stop being "enough" in two different ways.

The more common scenario: your fasting glucose is at goal on Tresiba, but your post-meal glucose and HbA1c remain elevated. This means basal coverage is working but you need help with post-meal spikes. The solution here is not to raise Tresiba further; excessive basal dosing without matching prandial insulin causes hypoglycemia between meals while post-meal glucose remains high. Adding empagliflozin or a GLP-1 receptor agonist is the appropriate next move.

The less common scenario: your fasting glucose is still high despite escalating Tresiba doses. This usually means you need to add prandial insulin at your largest meal rather than an SGLT2 inhibitor. Jardiance can still be added for cardiovascular and kidney benefits, but it will not solve the fasting hyperglycemia problem that more basal insulin is failing to fix.

Menstrual Cycle Titration for Tresiba

If you are premenopausal and still cycling, consider a two-dose Tresiba regimen: a base dose for your follicular phase and a slightly higher dose for the luteal phase. This is not FDA-approved as a formal dosing strategy, but it reflects published pharmacological reality. Progesterone at luteal-phase concentrations directly antagonizes insulin action at the receptor level, meaning fixed-dose basal insulin will predictably fall short in the second half of your cycle. Document your fasting glucose daily for two full cycles before concluding that your Tresiba dose needs a permanent upward adjustment.

Pregnancy, Lactation, and Contraception

This section is required reading if there is any chance you could become pregnant.

Jardiance in Pregnancy

Empagliflozin is contraindicated during the second and third trimesters of pregnancy. Animal studies showed fetal renal toxicity when SGLT2 inhibitors were given during the period of renal development, which in humans corresponds roughly to the second trimester onward. Human data are limited. The FDA labeling states that Jardiance should be discontinued as soon as pregnancy is detected. If you are sexually active and not using reliable contraception, discuss this with your clinician before starting or continuing Jardiance.

Jardiance is not recommended during the first trimester either, given the absence of safety data in human pregnancy. ACOG guidance is clear: insulin is the preferred glucose-lowering agent throughout pregnancy for women with pre-existing type 2 diabetes.

Tresiba in Pregnancy

Insulin degludec carries FDA Pregnancy Category B designation based on animal data. Human data are limited compared with insulin NPH or insulin glargine U-100, which have longer track records in pregnancy. The American Diabetes Association Standards of Care recommend insulin as the first-line pharmacological treatment for all types of diabetes in pregnancy. If you conceive on Tresiba, do not stop insulin. Continue and contact your maternal-fetal medicine team immediately, as your dose requirements will increase substantially across trimesters, often doubling or tripling by the third trimester.

Lactation

Jardiance: data are absent in lactating women. Animal studies show empagliflozin is present in rat milk. Because the drug affects renal glucose handling and developing kidney function, most clinicians advise against using Jardiance while breastfeeding.

Insulin degludec: insulin does not transfer meaningfully into breast milk, and what little might transfer is digested in the infant's gut and not absorbed systemically. Tresiba is considered compatible with breastfeeding. The LactMed database classifies basal insulin analogs as acceptable during lactation.

Contraception

If you are taking Jardiance and are sexually active with the possibility of pregnancy, you need reliable contraception. This means a method with a typical-use failure rate below 3%. Options include combined hormonal contraceptives, progestin-only pills, IUDs (hormonal or copper), or implants. Note that combined oral contraceptives can modestly worsen insulin resistance; your diabetes management may need minor adjustment if you start or stop hormonal contraception.

Who This Is Right For (and Who It Is Not)

Jardiance Is the Better Starting Point If You:

• Have established cardiovascular disease or high cardiovascular risk and your eGFR is above 20 mL/min/1.73m²
• Have heart failure with reduced or preserved ejection fraction
• Have chronic kidney disease with albuminuria
• Prefer oral medication over injections
• Are perimenopausal with worsening glycemic variability and do not yet need basal insulin
• Have PCOS with insulin resistance but not yet significant beta-cell failure

Tresiba Is the Better Starting Point If You:

• Have significant beta-cell failure and fasting glucose consistently above 180 mg/dL despite multiple oral agents
• Are pregnant or actively trying to conceive
• Have an eGFR below 45 mL/min/1.73m² where Jardiance's glucose-lowering effect is negligible
• Have recurrent vulvovaginal candidiasis that worsens on SGLT2 inhibitors
• Are postpartum and breastfeeding

Neither Is Appropriate Alone If You:

• Have type 1 diabetes (Jardiance can be used as an adjunct in type 1 with specialist supervision, but never as monotherapy)
• Are in diabetic ketoacidosis, even if your glucose is not dramatically elevated (euglycemic DKA risk with SGLT2 inhibitors is real)

PCOS: A Specific Note

Women with polycystic ovary syndrome have a 5- to 10-fold higher lifetime risk of developing type 2 diabetes compared with women without PCOS. The underlying mechanism is profound insulin resistance, often present years before beta-cell failure develops.

Jardiance is not FDA-approved for PCOS but carries biologically plausible benefit by reducing hyperinsulinemia through glucosuria. Tresiba, by contrast, would worsen the hyperinsulinemia that drives PCOS physiology if used before beta-cell failure is confirmed. Adding exogenous basal insulin in a woman with PCOS who still produces significant endogenous insulin is rarely appropriate.

Practical Cost and Access Considerations

The list price of Jardiance 10 mg (30-count) is approximately $600 per month without insurance. Empagliflozin is not yet generically available in the United States as of early 2025. Eli Lilly's insulin degludec (Tresiba) FlexTouch 100 U/mL lists at approximately $340 per 3 mL pen, with five pens per prescription. Rezenua, a biosimilar insulin degludec, received FDA approval and may reduce costs going forward.

Women on Medicaid may find formulary access to Jardiance restricted. The Eli Lilly insulin value program caps out-of-pocket costs at $35 per month for Tresiba for commercially insured patients.

Monitoring After Any Regimen Change

After adding Tresiba to Jardiance, or Jardiance to Tresiba, check:

• Fasting glucose daily for the first four weeks, targeting 80 to 130 mg/dL
• HbA1c at 12 weeks after the change
• eGFR and urine albumin-to-creatinine ratio at 12 weeks if starting Jardiance
• Body weight monthly; Jardiance typically produces 1 to 3 kg loss over three months, which can affect Tresiba dosing needs
• Signs of urinary tract infection and vulvovaginal symptoms weekly for the first month on Jardiance

Women who wear continuous glucose monitors should look specifically at nocturnal glucose patterns on Tresiba. If the sensor shows glucose below 70 mg/dL between 2 and 4 AM consistently, reduce Tresiba by 2 units before adjusting Jardiance.

The ADA Standards of Care recommend HbA1c below 7.0% for most non-pregnant adults with type 2 diabetes, with individualized targets for older adults or those with hypoglycemia unawareness. For women in the perimenopausal transition, where glycemic variability increases, time-in-range (70 to 180 mg/dL for at least 70% of the day) may be a more clinically meaningful target than HbA1c alone.